Uterine sarcoma: steroid receptors and response to hormonal therapy.
Seventy-three patients with uterine sarcomas were treated between 1976 and 1987. Steroid receptors were analyzed in 60 cases; 48% were estrogen receptor (ER) positive, and 30% progesterone receptor (PR) positive. Only 1 of 28 patients with residual or recurrent disease showed a response to hormonal therapy. Neither receptor status of the primary tumor nor use of adjuvant hormonal therapy affected survival.
Wade
K
K
Royal Women's Hospital, Melbourne, Perth, Australia.
Quinn
M A
MA
Hammond
I
I
Williams
K
K
Cauchi
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005187:Fallopian Tubes / Q000601:surgery; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D010052:Ovariectomy; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012509:Sarcoma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D016019:Survival Analysis; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology
D006728:Hormones; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone